<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111513</url>
  </required_header>
  <id_info>
    <org_study_id>PEJ-413</org_study_id>
    <nct_id>NCT01111513</nct_id>
  </id_info>
  <brief_title>The Influence of the Femoral Nerve Block on Quadriceps Strength</brief_title>
  <official_title>The Influence of the Femoral Nerve Block on the Quadriceps Strength After Total Knee Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital de l'Enfant-Jesus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hopital de l'Enfant-Jesus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total knee replacement is a frequent procedure in Québec's hospitals and the muscular
      strength of the quadriceps is the best indicator of the patient's functional recovery post
      surgery. Thus, the importance of the patient's recovery leads to the evaluation of the
      influence of the femoral nerve block on the muscle strength.

      The purpose of the study is to compare the short term and long term recuperation of the
      quadriceps' motor strength of after a total knee arthroplasty using different types of
      analgesics such as the continuous femoral nerve block, the single dose femoral nerve block
      and the systemic analgesic, a patient controlled analgesic pump.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quadriceps strength measurement with Cybex machine</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Evidence of the influence of the different types of analgesics on the strength of the quadriceps post surgery. Quadriceps strength will be evaluated in open chain and closed chain with the help of the Cybex machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quadriceps strength measurement with Cybex machine</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>Evidence of the influence of the different types of analgesics on the strength of the quadriceps post surgery. Quadriceps strength will be evaluated in open chain and closed chain with the help of the Cybex machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quadriceps strength measurements with Cybex machine</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Evidence of the influence of the different types of analgesics on the strength of the quadriceps post surgery. Quadriceps strength will be evaluated in open chain and closed chain with the help of the Cybex machine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall functional recovery</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>The overall functional recovery of the patient will be evaluated considering the analgesic type using SF-36 and WOMAC questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score on Visual Analog Scale (VAS)</measure>
    <time_frame>every 6 hour for the 48 hours following surgery</time_frame>
    <description>Evaluation of the effectiveness of the analgesics on pain with VAS .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay length</measure>
    <time_frame>4 to 7 days after surgery</time_frame>
    <description>Evaluation of the hospital stay length after total knee replacement taking into account the different types of analgesics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall functional recovery</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>The overall functional recovery of the patient will be evaluated considering the analgesic type using SF-36 and WOMAC questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall functional recovery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The overall functional recovery of the patient will be evaluated considering the analgesic type using SF-36 and WOMAC questionnaires.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Continuous femoral block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose femoral block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a single dose femoral block and have patient controlled analgesics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient controlled analgesics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients do not receive a femoral block. They only have patient controlled analgesics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>48-hour ropivacaine infusions</intervention_name>
    <description>Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.</description>
    <arm_group_label>Continuous femoral block</arm_group_label>
    <other_name>ropivacaine</other_name>
    <other_name>femoral block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose ropivacaine</intervention_name>
    <description>Patients receive 20 ml of ropivacaine 0.5% pre-operation</description>
    <arm_group_label>Single dose femoral block</arm_group_label>
    <other_name>ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patient controlled analgesics</intervention_name>
    <description>Patient controlled analgesics alone, no femoral block</description>
    <arm_group_label>Patient controlled analgesics</arm_group_label>
    <other_name>analgesics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old

          -  men or women needing an elective total knee replacement surgery

        Exclusion Criteria:

          -  unicompartmental arthroplasty

          -  revision surgery for knee arthroplasty

          -  previous surgery on same knee

          -  previous fracture of femur/patella with functional after-effects

          -  allergies or contraindication to any medication used during study or to local
             anaesthesia technique

          -  preexisting neurological deficit

          -  severe anomaly of intracardiac conduction

          -  previous vascular surgery near the site of introduction of the catheter

          -  pregnancy or breastfeeding

          -  ASA IV or V14 class

          -  Men or women &gt; 18 years old unfit to consent

          -  &lt; 18 years old

          -  Refusal to sign consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Pelet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Enfant-Jésus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michèle Angers, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Enfant-Jésus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA-Pavillon Enfant-Jésus</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hopital de l'Enfant-Jesus</investigator_affiliation>
    <investigator_full_name>Pelet Stephane</investigator_full_name>
    <investigator_title>Dr Stephane Pelet MD, PhD Orthopedic surgeon</investigator_title>
  </responsible_party>
  <keyword>knee surgery</keyword>
  <keyword>total knee arthroplasty</keyword>
  <keyword>total knee replacement</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>femoral nerve block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

